



ASX ANNOUNCEMENT

12 July 2022

PIONEERING INTERVENTIONAL CARDIOLOGIST JOINS GLOBAL MEDICAL ADVISORY BOARD

Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) welcomes Dr. Martin Leon, MD to Anteris' Global Medical Advisory Board.

Dr. Leon is a Professor of Medicine at Columbia University Medical Center. Dr. Leon is also Director of the Columbia Interventional Cardiovascular Care Center, Past Director of the Cardiac Catheterization Laboratories, and on the Executive Board of the Columbia New York Presbyterian Heart Valve Center in New York City. Dr. Leon is also the Founder and Chairmen Emeritus of the Cardiovascular Research Foundation and the Founder of Transcatheter Cardiovascular Therapeutics.

He is globally recognized as an early pioneer in the development of minimally invasive approaches to treating coronary and structural heart disease. He has served as a principal investigator for more than 75 landmark clinical trials that have shaped the field of interventional cardiology, co-authored more than 2,000 papers, and performed more than 10,000 procedures.

As a leader in the field of interventional cardiology and structural heart disease, Dr. Leon's involvement with Anteris will accelerate our progress in both product development and clinical science to bring validation for our novel DurAVR™ Transcatheter Heart Valve System for patients with severe aortic stenosis.

"I am excited Dr. Leon has agreed to join our Global Medical Advisory Board. His scientific curiosity and engineering insights align well with Anteris' focus to create life-changing solutions for patients with severe aortic stenosis," Anteris CEO, Wayne Paterson, said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

[Brisbane](#) • [Minneapolis](#) • [Geneva](#) • [Malaga](#)

**Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>